REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
REGENXBIO Inc. (Nasdaq: RGNX) has announced that data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be presented at the SSIEM 2024 Annual Symposium in Porto, Portugal from September 3-6, 2024. The presentation, titled 'CAMPSIITE™ phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II),' will be given by Dr. Roberto Giugliani on Wednesday, September 4, 2024, at 6:15 p.m. WEST. This presentation suggests ongoing progress in REGENXBIO's gene therapy research for MPS II.
REGENXBIO Inc. (Nasdaq: RGNX) ha annunciato che i dati del suo programma RGX-121 per il trattamento della mucopolisaccaridosi tipo II (MPS II), conosciuta anche come sindrome di Hunter, saranno presentati al SSIEM 2024 Annual Symposium a Porto, Portogallo, dal 3 al 6 settembre 2024. La presentazione, intitolata 'CAMPSIITE™ fase I/II/III: Aggiornamento clinico intermedio di RGX-121, una terapia genica sperimentale per il trattamento della mucopolisaccaridosi neuronopatica tipo II (MPS II),' sarà tenuta dal Dr. Roberto Giugliani mercoledì 4 settembre 2024, alle 18:15 WEST. Questa presentazione suggerisce progressi continui nella ricerca di terapia genica di REGENXBIO per l'MPS II.
REGENXBIO Inc. (Nasdaq: RGNX) ha anunciado que los datos de su programa RGX-121 para el tratamiento de la mucopolisacaridosis tipo II (MPS II), también conocida como síndrome de Hunter, serán presentados en el SSIEM 2024 Annual Symposium en Porto, Portugal, del 3 al 6 de septiembre de 2024. La presentación, titulada 'CAMPSIITE™ fase I/II/III: Actualización clínica intermedia de RGX-121, una terapia génica experimental para el tratamiento de la mucopolisacaridosis neuronopática tipo II (MPS II),' será impartida por el Dr. Roberto Giugliani el miércoles 4 de septiembre de 2024, a las 18:15 WEST. Esta presentación sugiere un progreso continuo en la investigación de terapia génica de REGENXBIO para la MPS II.
REGENXBIO Inc. (Nasdaq: RGNX)는 헌터 증후군으로도 알려진 형모양 교환병증 II형(MPS II)의 치료를 위한 RGX-121 프로그램의 데이터가 2024년 9월 3일부터 6일까지 포르투갈 포르투에서 열리는 SSIEM 2024 연례 심포지엄에서 발표된다고 밝혔습니다. 'CAMPSIITE™ 1/2/3기: 2형 전신 심한형 교환병증에 대한 연구자의 유전자 요법인 RGX-121의 중간 임상 업데이트'라는 제목의 발표는 2024년 9월 4일 수요일 오후 6:15 WEST에 로베르토 지울리아니 박사가 진행할 예정입니다. 이 발표는 MPS II에 대한 REGENXBIO의 유전자 요법 연구에서 지속적인 진전을 보여줍니다.
REGENXBIO Inc. (Nasdaq: RGNX) a annoncé que des données de son programme RGX-121 pour le traitement de la mucopolysaccharidose de type II (MPS II), également connue sous le nom de syndrome de Hunter, seront présentées au SSIEM 2024 Annual Symposium à Porto, au Portugal, du 3 au 6 septembre 2024. La présentation, intitulée 'CAMPSIITE™ phase I/II/III : Mise à jour clinique intermédiaire de RGX-121, une thérapie génique expérimentale pour le traitement de la mucopolysaccharidose neuronopathique de type II (MPS II),' sera faite par Dr. Roberto Giugliani le mercredi 4 septembre 2024, à 18h15 WEST. Cette présentation suggère des progrès continus dans la recherche sur la thérapie génique de REGENXBIO pour la MPS II.
REGENXBIO Inc. (Nasdaq: RGNX) hat angekündigt, dass Daten aus seinem RGX-121 Programm zur Behandlung der Mukopolysaccharidosen Typ II (MPS II), die auch als Hunter-Syndrom bekannt ist, auf dem SSIEM 2024 Jahres-Symposium in Porto, Portugal, vom 3. bis 6. September 2024 präsentiert werden. Die Präsentation mit dem Titel 'CAMPSIITE™ Phase I/II/III: Zwischenbericht zur klinischen Entwicklung von RGX-121, einer experimentellen Gentherapie zur Behandlung der neuronopathischen Mukopolysaccharidose Typ II (MPS II),' wird von Dr. Roberto Giugliani am Mittwoch, den 4. September 2024, um 18:15 Uhr WEST gehalten. Diese Präsentation deutet auf anhaltende Fortschritte in der Gentherapieforschung von REGENXBIO zur MPS II hin.
- Presentation of clinical data for RGX-121 program at a major symposium
- Ongoing development of gene therapy for MPS II (Hunter syndrome)
- None.
Abstract Title: CAMPSIITE™ phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II) (PO-205)
Presenter: Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA,
Date/Time: Wednesday, September 4, 2024; 6:15 p.m. WEST (Western European Summer Time)
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-2024-annual-symposium-302231163.html
SOURCE REGENXBIO Inc.
FAQ
What is REGENXBIO presenting at the SSIEM 2024 Annual Symposium?
When and where is the SSIEM 2024 Annual Symposium taking place?
Who is presenting the RGX-121 data for REGENXBIO (RGNX) at the symposium?
What is the title of REGENXBIO's (RGNX) presentation at the SSIEM 2024 symposium?
